Cargando…

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases

The ASXL1 gene is one of the most frequently mutated genes in malignant myeloid diseases. The ASXL1 protein belongs to protein complexes involved in the epigenetic regulation of gene expression. ASXL1 mutations are found in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), chronic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gelsi-Boyer, Véronique, Brecqueville, Mandy, Devillier, Raynier, Murati, Anne, Mozziconacci, Marie-Joelle, Birnbaum, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355025/ https://www.ncbi.nlm.nih.gov/pubmed/22436456 http://dx.doi.org/10.1186/1756-8722-5-12

Ejemplares similares

Myeloid malignancies: mutations, models and management
por: Murati, Anne, et al.
Publicado: (2012)

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
por: Devillier, Raynier, et al.
Publicado: (2015)

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias
por: Rocquain, Julien, et al.
Publicado: (2010)

Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes
por: Brecqueville, M, et al.
Publicado: (2011)

Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms
por: Brecqueville, M, et al.
Publicado: (2011)

Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification
por: Cervera, N, et al.
Publicado: (2017)

ASXL1/2 mutations and myeloid malignancies
por: Medina, Edward A., et al.
Publicado: (2022)

Erythroleukemia: Classification
por: Cervera, Nathalie, et al.
Publicado: (2023)

Loss of Asxl2 leads to myeloid malignancies in mice
por: Li, Jianping, et al.
Publicado: (2017)

Deregulation of tumor suppressive ASXL1−PTEN/AKT axis in myeloid malignancies
por: Cao, Lei, et al.
Publicado: (2020)

Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia
por: Fan, Yi, et al.
Publicado: (2021)

RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia
por: Bera, Rabindranath, et al.
Publicado: (2019)

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
por: Garciaz, Sylvain, et al.
Publicado: (2022)

Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes
por: Gelsi-Boyer, Véronique, et al.
Publicado: (2008)

Elevated Expression of ASXL2 is Associated with Poor Prognosis in Colorectal Cancer by Enhancing Tumorigenesis and Inducing Cell Proliferation
por: Cui, Ran, et al.
Publicado: (2020)

Multicolour-banding fluorescence in situ hybridisation (mbanding-FISH) to identify recurrent chromosomal alterations in breast tumour cell lines
por: Letessier, A, et al.
Publicado: (2005)

Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis
por: Asada, Shuhei, et al.
Publicado: (2018)

Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran
por: Parsa‐kondelaji, Mohammad, et al.
Publicado: (2022)

ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion
por: Madan, Vikas, et al.
Publicado: (2018)

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
por: Bidikian, Aram, et al.
Publicado: (2022)

Acute myeloid leukemia in a father and son with a germline mutation of ASXL1
por: Seiter, Karen, et al.
Publicado: (2018)

A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease
por: Johnson, Steven M., et al.
Publicado: (2023)

Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia
por: Kim, Hyun-Young, et al.
Publicado: (2018)

Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations
por: Nielsen, Helene Myrtue, et al.
Publicado: (2017)

The ASXL1-G643Wvariant accelerates the development of CEBPA mutant acute myeloid leukemia
por: D’Altri, Teresa, et al.
Publicado: (2020)

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
por: Schönfeld, Lioba, et al.
Publicado: (2022)

High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients
por: El Nahass, Yasser H, et al.
Publicado: (2022)

Examining the neurodevelopmental and motor phenotypes of Bohring-Opitz syndrome (ASXL1) and Bainbridge-Ropers syndrome (ASXL3)
por: Ayoub, Maya C., et al.
Publicado: (2023)

CRISPR/Cas9-mediated ASXL1 mutations in U937 cells disrupt myeloid differentiation
por: Wu, Zhi-Jie, et al.
Publicado: (2018)

Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex
por: Balasubramani, Anand, et al.
Publicado: (2015)

Publisher Correction: Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations
por: Nielsen, Helene Myrtue, et al.
Publicado: (2018)

ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia‐related changes and normal karyotype
por: Prats‐Martín, Concepción, et al.
Publicado: (2020)

A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation
por: Imataki, Osamu, et al.
Publicado: (2020)

Functional and cancer genomics of ASXL family members
por: Katoh, M
Publicado: (2013)

ASXL1 plays an important role in erythropoiesis
por: Shi, Hui, et al.
Publicado: (2016)

ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden
por: Wang, Yu-Hung, et al.
Publicado: (2020)

ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia
por: Menezes, J, et al.
Publicado: (2013)

Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network
por: Xia, Yu-Kun, et al.
Publicado: (2020)

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome
por: Castagna, Luca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jhh520nu5h2phdvlt7ibmedhic